Analysis of whether ruxolitinib cream (Opzelura) is included in medical insurance and reimbursement for patients

Ruxolitinib cream (Opzelura, also known as ruxolitinib ointment) has not yet been officially launched in China. Therefore, this drug has not yet been included in my country's medical insurance system. Due to the lack of domestic marketing and medical insurance reimbursement policy support, patients cannot purchase or reimburse the drug through medical insurance channels in China, and the cost of use is mainly borne by individuals.

Since it has not yet been launched in China, patients who need to use ruxolitinib cream must purchase it through regular overseas channels. This includes international pharmacies or overseas medical transport services, but you need to pay attention to the legality of drug sources and transportation safety to avoid purchasing irregular or counterfeit drugs. In addition, purchasing drugs overseas is usually accompanied by higher logistics costs and waiting times, and patients need to fully evaluate them before using them.

In overseas markets, the original drug price of ruxolitinib cream is relatively high, usually as high as more than 10,000 yuan. For patients with limited budgets, some countries such as Bangladesh provide relatively low prices for generic drugs, about a few hundred yuan per box, and the drug ingredients are basically the same as the original drugs, which can reduce the economic burden to a certain extent. However, patients should confirm the quality and legality of drugs when choosing.

When patients consider using ruxolitinib cream, they should make a decision based on their own financial ability, disease severity, and medication necessity. Before purchasing medicines overseas, it is recommended to consult a professional doctor or pharmacist to understand the correct usage, dosage and possible side effects management. At the same time, patients should pay attention to domestic drug approval trends. Once they are launched and included in medical insurance in the future, their out-of-pocket burden will be significantly reduced and treatment accessibility will be improved.

Reference materials:https://www.drugs.com/